I E Bezrukov

Krasnogorsk Hospital, Krasnogorsk, Russia.

1 publication 2025 – 2025 ORCID
RussiaIschemic StrokeFibrinolytic AgentsTissue Plasminogen ActivatorThrombolytic Therapy

What does I E Bezrukov research?

I E Bezrukov studies the use of Revelise, a medication that helps treat ischemic stroke, which occurs when blood flow to the brain is blocked. This research investigates how well this treatment works in everyday medical settings, especially among older patients and those with other health conditions. By examining real-world results, Bezrukov aims to improve stroke care and outcomes for patients, ensuring they receive the most effective treatment possible.

Key findings

  • In a study of 2,202 patients, 49.9% had good outcomes at discharge after receiving Revelise for ischemic stroke.
  • After 90 days, the rate of good outcomes increased to 66.4%, indicating significant recovery post-treatment.
  • The study demonstrated that Revelise effectively reduces stroke-related disabilities, benefiting older patients and those with multiple health issues.

Frequently asked questions

Does Dr. Bezrukov study ischemic stroke?
Yes, Dr. Bezrukov specializes in researching treatments for ischemic stroke, particularly the use of the medication Revelise.
What outcomes were found in Dr. Bezrukov's research?
In their study, nearly 50% of patients had good outcomes after treatment, which increased to over 66% after 90 days.
Is Dr. Bezrukov's work relevant to older patients?
Yes, Dr. Bezrukov's research highlights the effectiveness of Revelise in older patients and those with additional health concerns.

Publications in plain English

[Thrombolytic Therapy for Ischemic Stroke with Revelise: Results of a Two-Year Follow-Up in the International PRIMA Study].

2025

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova

Shamalov NA, Khasanova DR, Marchenko SV, Soldatov MA, Azarova AG +46 more

Plain English
This study looked at how well and safely Revelise (alteplase), a medication for treating ischemic stroke (IS), works in real-life situations. It involved 2,202 patients, mostly around 68 years old, and found that nearly half (49.9%) of them had good outcomes when discharged, rising to 66.4% after 90 days. The results showed that Revelise effectively reduces stroke-related disabilities, even in older patients and those with other health issues. Who this helps: This benefits patients who suffer from ischemic strokes and the doctors treating them.

PubMed

Publication data sourced from PubMed . Plain-English summaries generated by AI. Not medical advice.